Etoricoxib-induced erythema-multiforme-like eruption.
Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature.
Thirion
Laurence
L
Department of Dermatopathology, University Medical Center of Liège, Liège, Belgium.
Nikkels
Arjen F
AF
Piérard
Gérald E
GE
D000368:Aged; D001168:Arthritis / Q000188:drug therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000473:pathology; D000077613:Etoricoxib; D006801:Humans; D008297:Male; D011725:Pyridines / Q000009:adverse effects*; D012867:Skin / Q000473:pathology; D013450:Sulfones / Q000009:adverse effects*
D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D000077613:Etoricoxib